Share-based Payment Arrangement, Expense in USD of ROCKET PHARMACEUTICALS, INC. from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ROCKET PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from 2014 to Q3 2025.
  • ROCKET PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9,759,000, a 13% decline year-over-year.
  • ROCKET PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $42,035,000, a 1.7% decline year-over-year.
  • ROCKET PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $43,920,000, a 11% increase from 2023.
  • ROCKET PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $39,406,000, a 27% increase from 2022.
  • ROCKET PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $31,009,000, a 6.1% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ROCKET PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $42,035,000 $9,759,000 -$1,489,000 -13% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $43,524,000 $10,857,000 -$475,000 -4.2% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $43,999,000 $10,331,000 +$79,000 +0.77% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $43,920,000 $11,088,000 +$1,158,000 +12% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $42,762,000 $11,248,000 +$932,000 +9% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $41,830,000 $11,332,000 +$1,087,000 +11% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $40,743,000 $10,252,000 +$1,337,000 +15% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $39,406,000 $9,930,000 +$237,000 +2.4% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $39,169,000 $10,316,000 +$2,639,000 +34% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $36,530,000 $10,245,000 +$2,876,000 +39% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $33,654,000 $8,915,000 +$2,645,000 +42% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $31,009,000 $9,693,000 +$2,656,000 +38% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $28,353,000 $7,677,000 +$688,000 +9.8% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $27,665,000 $7,369,000 +$58,000 +0.79% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $27,607,000 $6,270,000 -$1,630,000 -21% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $29,237,000 $7,037,000 +$967,000 +16% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $28,270,000 $6,989,000 +$2,942,000 +73% 01 Jul 2021 30 Sep 2021 10-Q 04 Nov 2022 2022 Q3
Q2 2021 $25,328,000 $7,311,000 +$2,822,000 +63% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $22,506,000 $7,900,000 +$3,939,000 +99% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $18,567,000 $6,070,000 +$2,711,000 +81% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $15,856,000 $4,047,000 +$1,353,000 +50% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $14,503,000 $4,489,000 +$351,000 +8.5% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $14,152,000 $3,961,000 +$781,000 +25% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $13,371,000 $3,359,000 +$537,000 +19% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $12,834,000 $2,694,000 +$82,000 +3.1% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 $12,752,000 $4,138,000 +$1,353,000 +49% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $11,399,000 $3,180,000 -$2,202,000 -41% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $13,601,000 $2,822,000 +$2,462,000 +684% 01 Oct 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
Q3 2018 $11,139,000 $2,612,000 +$1,911,000 +273% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $9,228,000 $2,785,000 +$2,625,000 +1641% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $6,603,000 $5,382,000 +$5,283,000 +5336% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $1,320,000 $360,000 +$2,064,000 01 Oct 2017 31 Dec 2017 10-K 08 Mar 2019 2018 FY
Q3 2017 $744,000 $701,000 -$105,000 -13% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $639,000 $160,000 -$526,000 -77% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 $113,000 $99,000 -$387,000 -80% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018 2018 Q1
Q4 2016 $274,000 $1,704,000 01 Oct 2016 31 Dec 2016 10-K 08 Mar 2019 2018 FY
Q3 2016 $806,000 +$432,000 +116% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $686,000 +$492,000 +254% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $486,000 -$464,000 -49% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q3 2015 $374,000 01 Jul 2015 30 Sep 2015 10-Q 12 Nov 2015 2015 Q3
Q2 2015 $194,000 01 Apr 2015 30 Jun 2015 10-Q 07 Aug 2015 2015 Q2
Q1 2015 $950,000 01 Jan 2015 31 Mar 2015 10-Q 11 May 2016 2016 Q1

ROCKET PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $43,920,000 +$4,514,000 +11% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $39,406,000 +$8,397,000 +27% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $31,009,000 +$1,772,000 +6.1% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $29,237,000 +$10,670,000 +57% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $18,567,000 +$5,196,000 +39% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $13,371,000 -$230,000 -1.7% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $13,601,000 +$12,281,000 +930% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
2017 $1,320,000 +$1,046,000 +382% 01 Jan 2017 31 Dec 2017 10-K 08 Mar 2019 2018 FY
2016 $274,000 01 Jan 2016 31 Dec 2016 10-K 08 Mar 2019 2018 FY
2014 $7* 01 Jan 2014 31 Dec 2014 10-K 23 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.